remdesevir - versus standard of care - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.65 [0.21, 2.01]< 10%2 studies (2/-)77.2 %some concernnot evaluable moderatecrucial-
clinical improvement 1.38 [0.98, 1.95]> 130%2 studies (2/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.57 [1.15, 2.16]> 10%2 studies (2/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.81 [1.19, 2.76]> 10%2 studies (2/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.25 [0.84, 1.85]> 146%2 studies (2/-)86.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 95,94,90,91 90